Development of an Anti-GM-CSF Antibody for Treatment of Rheumatoid Arthritis

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/381407

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

The aim of this project is to develop assays for the evaluation of the efficacy and safety of an anti-GMCSF neutralizing antibody in a Australian first-in-man clinical trial in patients with severe rheumatoid arthritis (RA). This chimeric antibody has been developed by the Ludwig Institute for Cancer Research, Melbourne Branch, in conjunction with KaloBios Pharmaceuticals, Inc., USA. It is intended to use the assays developed in this project to facilitate commercial development of this antibody, and result in the development of an improved treatment for this devastating disease.

Funded Activity Details

Start Date: 01-01-2006

End Date: 01-01-2007

Funding Scheme: NHMRC Development Grants

Funding Amount: $283,000.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Rheumatology and Arthritis

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

Anti-inflammatory | Clinical research | Immunodiagnostic technique | Monoclonal antibody | Rheumatoid arthritis

Related Links